Needham & Company Reiterates a 'Buy' on Vivus (VVUS); Retrospective Topiramate Study to be Underway Soon, with Results Likely in 4Q11

Needham & Company reiterates a 'Buy' on Vivus (NASDAQ: VVUS), PT $15.

Needham analyst says, "Vivus provided a quarterly update in a conference call last night. The company has reportedly reached agreement with the FDA on design of a retrospective analysis of topiramate risk for birth defects in children. This study is expected to be underway soon. With a positive outcome, management is guiding for resubmission of an NDA by YE11. We continue to believe that the potential risks associated with topiramate/phentermine are manageable and project approval in 2012, following a 6-month FDA review. We believe the stock is undervalued at $500MM EV and reiterate our rating."

For more ratings news on Vivus click here and for the rating history of Vivus click here.

Shares of Vivus closed at $7.80 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• TSS Inc (TSSI) PT Lowered to $13 at Needham
• Wolverine World Wide (WWW) PT Raised to $24 at Needham